1-叠氮基-1-脱氧-D-半乳糖醛酸酯2,3,4-三乙酸酯甲酯 | 67776-38-9

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡喃类化合物
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-叠氮基-1-脱氧-D-半乳糖醛酸酯2,3,4-三乙酸酯甲酯
• 中文别名: 6-氨基-5-(4-磺酰胺基苯甲酰基)-N-(甲基氨基)-1-甲基尿嘧啶
• 英文名称: 2,3,4-tri-O-acetyl-1-azido-1-deoxy-β-D-glucopyranuronic acid methyl ester
• 英文别名: (2R,3R,4S,5S,6S)-2-azido-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate；methyl 1-azido-1-deoxy-β-D-glucopyranuronate 2,3,4-triacetate；methyl (2S,3S,4S,5R,6R)-3,4,5-triacetyloxy-6-azidooxane-2-carboxylate
• CAS: 67776-38-9
• 化学式: C₁₃H₁₇N₃O₉
• 分子量: 359.293
• InChiKey: PMUZMIKGOMUGFG-HHHUOAJASA-N

物化性质

• 熔点：
  153 °C
• 溶解度：
  可溶于氯仿（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  25
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.69
• 拓扑面积：
  129
• 氢给体数：
  0
• 氢受体数：
  11

安全信息

• 储存条件：
  -20°C

反应信息

• 作为反应物：
  描述：

  1-叠氮基-1-脱氧-D-半乳糖醛酸酯2,3,4-三乙酸酯甲酯 在 palladium on activated charcoal 4-二甲氨基吡啶 、 氢气 、 1-羟基苯并三唑 、 N,N'-二环己基碳二亚胺 作用下， 以 四氢呋喃 为溶剂， 反应 12.0h， 生成 (2S,3S,4S,5R,6R)-3,4,5-Triacetoxy-6-(2-biphenyl-4-yl-acetylamino)-tetrahydro-pyran-2-carboxylic acid methyl ester
  参考文献：
  名称：

  Synthesis of a glucuronic acid and glucose conjugate library and evaluation of effects on endothelial cell growth

  摘要：

  Compounds that alter endothelial cell growth are of interest in the development of angiogenesis modulators. A structurally diverse series of saccharide derivatives (glycosylamide conjugates) have been synthesized and evaluated for their effects on bovine aortic endothelial cell (BAEC) growth. Heparin-albumin (HA) reduced BAEC growth by 32% at 10 mug/mL and a number of the novel saccharide conjugates from the library were found to mimic the effect of HA as they also inhibit endothelial cell survival under identical conditions. Two thiophene conjugates, thioglucamide (24% inhibition at 35 muM) and a related glucuronide (26% inhibition at 33 muM) were the most potent inhibitors of BAEC growth, as determined using a methylthiazol tetrazoliurn (MTT) assay. The effects of thioglucamide and HA on absolute cell number were also studied using cell counting experiments; thioglucamide (47% after 24 h) was more potent than indicated by the MTT assay and initially reduced the BAEC number to a greater extent than HA (30% after 24 h); however, its actions were over more rapidly than were HA's as cell growth had returned to levels of the control after 72 h where HA still caused 25% inhibition. The binding of the monosaccharide conjugates to fibroblast growth factor (FGF-2) in competition with heparin-alburnin by ELISA was investigated to establish the possible mechanism by which glycoconjugates could alter growth but there was no general correlation between reduction in viable cell population and binding to FGF-2. No glycoconjugate reduced the proliferation of mouse mammary epithelial cells, nor did any alter gross cell morphology, supporting a proposal that the reduction in BAEC survival by monosaccharide conjugates such as thioglucamide is a result of the inhibition of cell proliferation rather than being an induction of cytotoxicity. These studies indicate that cell biological studies to determine the mechanism of action of the simple monosaccharide conjugates may be worthwhile. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.carres.2004.05.024
• 作为产物：
  描述：

  D-GLUCURONIDEMETHYLESTERD-葡糖苷酸甲酯 在 叠氮基三甲基硅烷 、 sodium acetate 、 四氯化锡 作用下， 以 二氯甲烷 为溶剂， 反应 11.0h， 生成 1-叠氮基-1-脱氧-D-半乳糖醛酸酯2,3,4-三乙酸酯甲酯
  参考文献：
  名称：

  含糖氨基酸的线性和环状肽的合成和构象分析

  摘要：

  糖氨基酸 (SAA) 被设计和合成为新的非肽肽模拟物，利用碳水化合物作为肽构建块。它们代表带有氨基和羧基官能团的类糖环结构，并且由于它们在刚性吡喃糖环中的不同取代模式，因此对肽的骨架具有特定的构象影响。已经合成了五种不同的 SAA（SAA1α、SAA1β、SAA2、SAA3 和 SAA4），它们显示出限制线性骨架构象或不同转角结构的能力。涉及 SAA 的线性和环状肽已在溶液中以及通过固相合成制备。SAA1α 和 SAA2 被整合到两个线性亮氨酸-脑啡肽类似物中，取代了天然的 Gly-Gly 二肽。NMR 研究为碳水化合物部分的构象诱导作用提供了证据。SAA2 和 SAA3 已被置于生长抑素的环状六肽类似物中；SAA4 被掺入模型肽中。的构造...

  DOI：

  10.1021/ja961068a

文献信息

• ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
  申请人：AbbVie Inc.

  公开号：US20170355769A1

  公开（公告）日：2017-12-14

  The invention relates to B7 homology 3 protein (B7-H3) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

  这项发明涉及B7同源物3蛋白（B7-H3）抗体和抗体药物结合物（ADCs），包括使用所述抗体和ADCs的组合物和方法。
• A Generalized Procedure for the One-Pot Preparation of Glycosyl Azides and Thioglycosides Directly from Unprotected Reducing Sugars under Phase-Transfer Reaction Conditions
  作者：Rishi Kumar、Pallavi Tiwari、Prakas R. Maulik、Anup K. Misra

  DOI：10.1002/ejoc.200500646

  日期：2006.1

  Per-O-acetylated glycosyl azides and thioglycosides were prepared in excellent yield directly from unprotected reducing sugars through in situ generation of per-O-acetylated glycosyl bromides by a generalized one-pot procedure under phase-transfer conditions. Stereoselective products were formed with complete inversion at the anomeric centers of the glycosyl bromides to provide a general high-yielding

  过氧乙酰化糖基叠氮化物和硫代糖苷直接从未保护的还原糖通过通用的一锅法在相转移条件下原位生成过氧乙酰化糖基溴化物，以优异的收率制备。在糖基溴化物的异头中心完全反转形成立体选择性产物，为制备 1,2-反式糖基叠氮化物和硫代糖苷提供了一种通用的高产率方法。（© Wiley-VCH Verlag GmbH & Co. KGaA， 69451 德国魏因海姆，2006）
• [EN] ANTI-EGFR ANTIBODY DRUG CONJUGATES<br/>[FR] CONJUGUÉ ANTICORPS-MÉDICAMENT ANTI-EGFR
  申请人：ABBVIE INC

  公开号：WO2017214282A1

  公开（公告）日：2017-12-14

  The invention relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods of using said ADCs. Formula (IIa), (IIb), (IIc)

  本发明涉及抑制Bcl-xL的抗表皮生长因子受体（EGFR）抗体药物偶联物（ADCs），包括所述ADCs的组成和方法。公式（IIa），（IIb），（IIc）
• [EN] BCL XL INHIBITORY COMPOUNDS HAVING LOW CELL PERMEABILITY AND ANTIBODY DRUG CONJUGATES INCLUDING THE SAME<br/>[FR] COMPOSÉS INHIBITEURS DE BCL XL AYANT UNE FAIBLE PERMÉABILITÉ CELLULAIRE ET CONJUGUÉS ANTICORPS-MÉDICAMENT COMPRENANT CEUX-CI
  申请人：ABBVIE INC

  公开号：WO2016094509A1

  公开（公告）日：2016-06-16

  The present disclosure concerns Bcl-xL inhibitors having low cell permeability, antibody drug conjugates (ADCs) comprising the inhibitors, synthons useful for synthesizing the ADCs, compositions comprising the inhibitors or ADCs, and various methods of using the inhibitors and ADCs.

  本公开涉及具有低细胞渗透性的Bcl-xL抑制剂，包括这些抑制剂的抗体药物结合物（ADCs），用于合成ADCs的合成子，包括这些抑制剂或ADCs的组合物，以及使用这些抑制剂和ADCs的各种方法。
• OLIGONUCLEOTIDE DERIVATIVE, OLIGONUCLEOTIDE CONSTRUCT USING THE SAME, AND METHODS FOR PRODUCING THEM
  申请人：GIFU UNIVERSITY

  公开号：US20180094017A1

  公开（公告）日：2018-04-05

  The oligonucleotide derivative of the present invention is represented by Formula (1). This derivative is considered to be introduced into cells by binding of its amino sugar chain moiety to a ligand on cell surfaces, and have selective drug delivery function. The oligonucleotide derivative can be easily synthesized and introduced into cells without using a lipofection reagent. wherein—A and B are independently modified or unmodified oligonucleotides whose total chain length is 3 or more, and A and B do not contain hydroxyl groups at 3′ and 5′ ends of the oligonucleotide; S represents a sugar substituent, a peptide chain, or a tocopherol-binding group; and an alkyl group may be bound instead of hydrogen bound to a benzene ring.

  本发明的寡核苷酸衍生物由式（1）表示。该衍生物被认为通过其氨基糖链部分与细胞表面的配体结合而被引入细胞，并具有选择性药物传递功能。该寡核苷酸衍生物可以在不使用脂质体载体的情况下轻松合成并引入细胞。其中，A和B分别是经修饰或未经修饰的寡核苷酸，其总链长为3或更长，且A和B不含有寡核苷酸的3′和5′末端的羟基；S代表糖取代基、肽链或生育酚结合基；和烷基基团可以与苯环上的氢结合而不是氢结合。